2018 Annual Meeting | C215 - Case Studies in Behavioral Neurology: Focus on Frontotemporal Degeneration
06:30 PM - 07:00 PM | Speaker |
Overview / Cases of FTD-PPA Spectrum
Daniel Kaufer, MD, FAAN |
07:00 PM - 07:30 PM | Speaker |
Overview / Cases of PSP-CBD Spectrum
Irene Litvan, MD, FAAN |
07:30 PM - 08:00 PM | Speaker |
Overview / Cases of bvFTD Spectrum
Howard J. Rosen, MD |
08:00 PM - 08:15 PM | Break |
Break
|
08:15 PM - 09:00 PM | Speaker |
Case Presentations
Daniel Kaufer, MD, FAAN, Irene Litvan, MD, FAAN, Howard J. Rosen, MD |
Daniel Kaufer, MD, FAAN | No disclosure on file |
Irene Litvan, MD, FAAN | Dr. Litvan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aprinoia. Dr. Litvan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Litvan has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology. Dr. Litvan has received personal compensation in the range of $50,000-$99,999 for serving as a Chief Editor with Frontiers in Neurology. |
Howard J. Rosen, MD | Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharmaceuticals. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Alector that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities. |